Abstract
This entry presents an overview of how real-world administrative data, routinely available as part of clinical practice within healthcare systems, can be used to generate real-world evidence to inform regulators, support policy formation and monitoring, shape service delivery, and improve patient care. We outline in brief the methods that can be applied to these data, incorporating strengths, weaknesses, opportunities, and challenges with the use of aggregate and individual-level data, respectively. We complete with illustrations, from the authors’ own experiences, of how real-world data can drive, both within countries and across countries, improvement in patient care as part of public health and drug programs.
This is a preview of subscription content, log in via an institution to check access.
References
Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data resource profile: the Scottish national prescribing information system (PIS). Int J Epidemiol. 2016;45(3):714–715f.
Barnett KN, Bennie M, Treweek S, Robertson C, Petrie DJ, Ritchie LD, et al. Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS) a pragmatic three-arm cluster randomised trial: designing the intervention (ClinicalTrials.gov registration NCT01602705). Implement Sci. 2014;9(1):133.
Bennie M, Malcolm W, Marwick CA, Kavanagh K, Sneddon J, Nathwani D. Building a national infection intelligence platform to improve antimicrobial stewardship and drive better patient outcomes: the Scottish experience. J Antimicrob Chemother. 2017;72(10):2938–42.
Bennie M, Kurdi A, MacBride-Stewart S, Avery T. Medication safety in primary care-from measurement to action. Drug Ther Bull. 2021;59(2):24–8.
Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–5.
Cai C, Peng Y, Shen E, Huang Q, Chen Y, Liu P, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther. 2021;29(9):2794–805.
Califf RM, Hernandez AF, Landray M. Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomized harmony. JAMA. 2020;324(7):625–6.
Campbell S, Wettermark B, Andersen M. Defining and developing quality indicators for drug utilization. In: Drug utilization research [Internet]. Wiley; 2016 [cited 2021 Nov 7]. p. 126–38. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118949740.ch12
Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Therap. 2019;106(1):36–9.
Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;20(371):m3731.
Data collections – WHO [Internet]. 2021 [cited 2021 Nov 7]. Available from: https://www.who.int/data/collections
Elseviers M, editor. Drug utilization research: methods and applications. Chichester/Hoboken: Wiley; 2016.
ElZarrad MK, Corrigan-Curay J. The US food and drug administration’s real-world evidence framework: a commitment for engagement and transparency on real-world evidence. Clin Pharmacol Therap. 2019;106(1):33–5.
Eriksson I, Ibáñez L. Secondary data sources for drug utilization research. In: Drug Utilization Research [Internet]. Wiley; 2016 [cited 2021 Nov 7]. p. 39–48. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118949740.ch4
European Centre for Disease Prevention and Control. Disease and laboratory networks [Internet]. European Centre for Disease Prevention and Control. 2021 [cited 2021 Nov 7]. Available from: https://www.ecdc.europa.eu/en/about-us/who-we-work/disease-and-laboratory-networks
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Search Database [Internet]. 2021a [cited 2021 Nov 7]. Available from: http://www.encepp.eu/encepp/search.htm
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP Guide on methodological standards in pharmacoepidemiology [Internet]. 2021b [cited 2021 Nov 22]. Available from: https://www.encepp.eu/standards_and_guidances/methodologicalGuide5.shtml
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative. Circulation. 2021;143(10):1002–13.
Fujita K, Moles RJ, Chen TF. Quality indicators for responsible use of medicines: a systematic review. BMJ Open. 2018;8(7):e020437.
Gatto NM, Reynolds RF, Campbell UB. A structured Preapproval and postapproval comparative study design framework to generate valid and transparent real-world evidence for regulatory decisions. Clin Pharmacol Ther. 2019 Jul;106(1):103–15.
Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life. 2021;11(6):528.
Grange Z, Buelo A, Sullivan C, Moore E, Agrawal U, Boukhari K, et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. Lancet. 2021;398(10313):1799–800.
Guthrie B, Kavanagh K, Robertson C, Barnett K, Treweek S, Petrie D, et al. Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. BMJ. 2016;354:i4079.
Health Protection Scotland. Scottish one health antimicrobial use and antimicrobial resistance in 2019 [Internet]. 2021 [cited 2021 Nov 22]. Available from: https://www.hps.scot.nhs.uk/web-resources-container/scottish-one-health-antimicrobial-use-and-antimicrobial-resistance-in-2019/
Healthcare Improvement Scotland. Safeguarding antibiotics for Scotland, now and for the future [Internet]. Scottish Antimicrobial Prescribing Group. [cited 2021 Nov 22]. Available from: https://www.sapg.scot/
Hernán MA. The C-Word: scientific euphemisms do not improve causal inference from observational data. Am J Public Health. 2018;108(5):616–9.
Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47.
Kavanagh K, Pan J, Marwick C, Davey P, Wiuff C, Bryson S, et al. Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data. J Antimicrob Chemother. 2017;72(4):1193–201.
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722–30.
Malcolm W, Fletcher E, Kavanagh K, Deshpande A, Wiuff C, Marwick C, et al. Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland infection intelligence platform. J Antimicrob Chemother. 2018;73(1):223–30.
Miksad RA, Abernethy AP. Harnessing the Power of Real-World Evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther. 2018 Feb;103(2):202–5.
Mueller T, Kerr S, McTaggart S, Kurdi A, Vasileiou E, Docherty A, et al. Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study. BMJ Open. 2021;11(11):e054861.
Office for Statistics Regulation. Administrative data (part 1) [Internet]. 2021 [cited 2021 Oct 12]. Available from: https://osr.statisticsauthority.gov.uk/guidance/administrative-data-and-official-statistics/quality-assurance-of-administrative-data-case-examples/administrative-data-part-1/
Organisation for Economic Co-operation and Development. Health – OECD [Internet]. [cited 2021 Nov 7]. Available from: https://www.oecd.org/health/
Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021:1–10.
Pearce N. The ecological fallacy strikes back. J Epidemiol Commun Health. 2000;54(5):326–7.
Public Health Scotland. Infection intelligence platform [Internet]. 2020 [cited 2021 Nov 22]. Available from: https://www.isdscotland.org/Health-Topics/Health-and-Social-Community-Care/Infection-Intelligence-Platform/About-IIP/
Public Health Scotland. COVID-19 Shielding programme – COVID-19 data and intelligence – COVID-19 – Our areas of work – Public Health Scotland [Internet]. 2021a [cited 2021 Oct 12]. Available from: https://www.publichealthscotland.scot/our-areas-of-work/covid-19/covid-19-data-and-intelligence/covid-19-shielding-programme/
Public Health Scotland. How we share data and intelligence – Sharing our data and intelligence – Our areas of work – Public Health Scotland [Internet]. 2021b [cited 2021 Nov 7]. Available from: https://publichealthscotland.scot/our-areas-of-work/sharing-our-data-and-intelligence/how-we-share-data-and-intelligence/
Public Health Scotland. Community Health Index (CHI) Number | ISD Scotland | Data Dictionary [Internet]. 2021c. [cited 2021 Nov 7]. Available from: https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets//Patient-Identification-and-Demographic-Information/Community-Health-Index-Number/
Public Health Scotland. National therapeutic indicators data visualisation [Internet]. 2021d [cited 2021 Nov 23]. Available from: https://publichealthscotland.scot/publications/national-therapeutic-indicators-data-visualisation/national-therapeutic-indicators-data-visualisation-data-to-june-2021/
Publications Office of the European Union. Datasets – data.europa.eu [Internet]. [cited 2021 Nov 7]. Available from: https://data.europa.eu/data/datasets?locale=en&categories=HEAL&page=1&query=medicine
Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov. JAMA Intern Med. 2020;180(10):1398–400.
Ramamoorthy A, Huang S-M. What does it take to transform real-world data into real-world evidence? Clin Pharmacol Therap. 2019;106(1):10–8.
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19–27.
Robertson J, Iwamoto K, Hoxha I, Ghazaryan L, Abilova V, Cvijanovic A, et al. Antimicrobial medicines consumption in Eastern Europeand Central Asia – an updated cross-national study and assessment of quantitativemetrics for policy action. Front Pharmacol. 2019;9:1156.
Schneeweiss S. Real-world evidence of treatment effects: the useful and the misleading. Clin Pharmacol Therap. 2019;106(1):43–4.
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Resp Med. 2020;8(11):1106–20.
Schurman B. The framework for FDA’s real-world evidence program. Appl Clin Trial. 2019;28(4):15–7.
Scottish Government. Achieving excellence in pharmaceutical care: a strategy for Scotland [Internet]. 2017 [cited 2021 Nov 23]. Available from: http://www.gov.scot/publications/achieving-excellence-pharmaceutical-care-strategy-scotland/
Scottish Government. Polypharmacy guidance realistic prescribing, 3rd edition [Internet]. 2018a [cited 2021 Nov 23]. Available from: https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/04/Polypharmacy-Guidance-2018.pdf
Scottish Government. National therapeutic indicators and additional prescribing measures 2017/2018 [Internet]. 2018b [cited 2021 Nov 23]. Available from: https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2017/07/NTI-17-18-Early-release-document-v1.0.pdf
Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2.
Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290–7.
Slattery J, Kurz X. Assessing strength of evidence for regulatory decision making in licensing: what proof do we need for observational studies of effectiveness? Pharmacoepidemiol Drug Safe. 2020;29(10):1336–40.
Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5 Chichester: Wiley-Blackwell; 2012. 953 p
Thomas J. Medical records and issues in negligence. Indian J Urol. 2009;25(3):384–8.
UK Government. Antimicrobial resistance (AMR) [Internet]. GOV.UK. 2019 [cited 2021 Nov 22]. Available from: https://www.gov.uk/government/collections/antimicrobial-resistance-amr-information-and-resources
University of Edinburgh. EAVE II [Internet]. The University of Edinburgh. [cited 2021 Jun 8]. Available from: https://www.ed.ac.uk/usher/eave-ii
University of Oxford. OpenSAFELY: secure analytics platform for NHS electronic health records [Internet]. 2021 [cited 2021 Nov 23]. Available from: https://www.opensafely.org/
Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646–57.
Virnig BA, McBean M. Administrative data for public health surveillance and planning. Annual Rev Pub Health. 2001;22(1):213–30.
Weir NM, Newham R, Corcoran ED, Ali Atallah Al-Gethami A, Mohammed Abd Alridha A, Bowie P, et al. Application of process mapping to understand integration of high risk medicine care bundles within community pharmacy practice. Res Soc Admin Pharm. 2018;14(10):944–50.
Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to medicaid enrollees. Health Affairs. 2017;36(4):733–41.
Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010 May;17(10):128.
Wettermark B, Elseviers M, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al. Introduction to drug utilization research. In: Drug utilization research [Internet]. Wiley; 2016 [cited 2021 Nov 7]. p. 1–12. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118949740.ch1
WHO Collaborating Centre for Drug Statistics Methodology. WHOCC – History [Internet]. 2018a [cited 2021 Nov 7]. Available from: https://www.whocc.no/atc_ddd_methodology/history/
WHO Collaborating Centre for Drug Statistics Methodology. WHOCC – Definition and general considerations [Internet]. 2018b [cited 2021 Nov 7]. Available from: https://www.whocc.no/ddd/definition_and_general_considera/
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Rheumatic Dis. 2021;80(7):943–51.
World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: World Health Organization; 2015 [cited 2021 Nov 7]. 28 p. Available from: https://apps.who.int/iris/handle/10665/193736
World Health Organization. Medication without harm [Internet]. 2017 [cited 2021 Nov 7]. Available from: https://www.who.int/initiatives/medication-without-harm
World Health Organization. Coronavirus disease (COVID-19) [Internet]. 2021 [cited 2021 Nov 23]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
World Medical Association. WMA declaration of Helsinki – ethical principles for medical research involving human subjects [Internet]. 2021 [cited 2021 Oct 13]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
Author information
Authors and Affiliations
Corresponding author
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Bennie, M., Kurdi, A., Mueller, T. (2022). Using Administrative Data from Public Health and Drug Programs. In: Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-50247-8_61-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-50247-8_61-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-50247-8
Online ISBN: 978-3-030-50247-8
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences